Figure 2.
Impaired megakaryocyte development in Agkf/fPF4-Cre mice. (A) Immunohistochemical images of CD42c in femurs and spleens of Agkf/f mice and Agk−/− mice. The scale bars represent 30 μm. Statistics for the megakaryocytes in femur (FM) and spleen (SP) sections of Agkf/f mice and Agk−/− mice are shown (n = 13; ***P < .001). (B) CD41+CD42b+ megakaryocytes in BM and spleen samples were detected by flow cytometry. Statistics for the CD41+CD42b+ megakaryocytes in the BM (n = 6; ***P < .001) and spleen (n = 5; **P < .01) samples of Agkf/f mice and Agk−/− mice are shown. (C) Spleens of Agkf/f mice and Agk−/− mice. (D) Splenectomies were performed on Agkf/f mice and Agk−/− mice, and circulating platelet were counted at indicated time points (n = 5; *P < .05, **P < .01, ***P < .001). (E) Megakaryocyte colony-forming unit (MK-CFU) assay using BM cells harvested from Agkf/f mice and Agk−/− mice (n = 3; *P < .05). (F) Megakaryocyte colony-forming unit assay using sorted MKP cells from fetal liver of Agkf/f mice and Agk−/− mice (n = 3; **P < .01). (G) The level of TPO in the plasma from Agkf/f mice and Agk−/− mice (n = 6). (H) Immunofluorescence images of α-tubulin in PPF-megakaryocytes derived from the fetal livers of Agkf/f mice and Agk−/− mice. Scale bars, 50 μm. Statistics for the PPF-megakaryocytes/total megakaryocytes derived from the fetal livers of Agkf/f mice and Agk−/− mice are shown (n = 10; ***P < .001). (I) Percentage of megakaryocytes polyploidy derived from fetal liver of Agkf/f and Agk−/− mice (n = 3; *P < .05, **P < .01, ***P < .001). DAPI, 4′,6-diamidino-2-phenylindole; MK, megakaryocyte; MKP, megakaryocyte progenitor.

Impaired megakaryocyte development in Agkf/fPF4-Cre mice. (A) Immunohistochemical images of CD42c in femurs and spleens of Agkf/f mice and Agk−/− mice. The scale bars represent 30 μm. Statistics for the megakaryocytes in femur (FM) and spleen (SP) sections of Agkf/f mice and Agk−/− mice are shown (n = 13; ***P < .001). (B) CD41+CD42b+ megakaryocytes in BM and spleen samples were detected by flow cytometry. Statistics for the CD41+CD42b+ megakaryocytes in the BM (n = 6; ***P < .001) and spleen (n = 5; **P < .01) samples of Agkf/f mice and Agk−/− mice are shown. (C) Spleens of Agkf/f mice and Agk−/− mice. (D) Splenectomies were performed on Agkf/f mice and Agk−/− mice, and circulating platelet were counted at indicated time points (n = 5; *P < .05, **P < .01, ***P < .001). (E) Megakaryocyte colony-forming unit (MK-CFU) assay using BM cells harvested from Agkf/f mice and Agk−/− mice (n = 3; *P < .05). (F) Megakaryocyte colony-forming unit assay using sorted MKP cells from fetal liver of Agkf/f mice and Agk−/− mice (n = 3; **P < .01). (G) The level of TPO in the plasma from Agkf/f mice and Agk−/− mice (n = 6). (H) Immunofluorescence images of α-tubulin in PPF-megakaryocytes derived from the fetal livers of Agkf/f mice and Agk−/− mice. Scale bars, 50 μm. Statistics for the PPF-megakaryocytes/total megakaryocytes derived from the fetal livers of Agkf/f mice and Agk−/− mice are shown (n = 10; ***P < .001). (I) Percentage of megakaryocytes polyploidy derived from fetal liver of Agkf/f and Agk−/− mice (n = 3; *P < .05, **P < .01, ***P < .001). DAPI, 4′,6-diamidino-2-phenylindole; MK, megakaryocyte; MKP, megakaryocyte progenitor.

Close Modal

or Create an Account

Close Modal
Close Modal